JNJ-77242113 for Plaque Psoriasis
(ICONIC-TOTAL Trial)

Recruiting in Palo Alto (17 mi)

+106 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Janssen Research & Development, LLC

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new medication called JNJ-77242113 to see if it can help people with plaque psoriasis in hard-to-treat areas like the scalp, genital area, and palms/soles. The medication works by calming the immune system and slowing down skin cell growth. The goal is to find a more effective treatment for these challenging cases.

Eligibility Criteria

This trial is for people who've had plaque psoriasis, including on the scalp, genitals, or palms and soles of the feet, for at least half a year. They should need systemic treatment or phototherapy and have tried at least one topical therapy without success. Participants must not have non-plaque psoriasis types or skin conditions that could interfere with the study.

Inclusion Criteria

I have plaque psoriasis on parts of my body other than my scalp, genitals, or palms/soles.

I am eligible for light therapy or medication for my plaque psoriasis.

I have been diagnosed with plaque psoriasis for at least 6 months.

+2 more

Exclusion Criteria

My psoriasis started or got worse after taking certain medications.

I do not have severe or worsening problems with my kidneys, liver, heart, blood vessels, lungs, stomach, hormones, nerves, blood, joints, mind, or metabolism.

My psoriasis is not the plaque type but another form like guttate or pustular.

+2 more

Participant Groups

The trial tests JNJ-77242113's effectiveness against placebo in treating plaque psoriasis in sensitive areas. It aims to see if this new medication can improve symptoms better than a non-active treatment (placebo).

2Treatment groups

Experimental Treatment

Placebo Group

Group I: JNJ-77242113Experimental Treatment1 Intervention

Participants will receive JNJ-77242113 from Week 0 through Week 156.

Group II: PlaceboPlacebo Group2 Interventions

Participants will receive placebo from Week 0 through Week 16 and thereafter will receive JNJ-77242113 from Week 16 through Week 156.